Display options
Cite
Iwata H, Osborn EA, Ughi GJ, et al. Highly Selective PPARα (Peroxisome Proliferator-Activated Receptor α) Agonist Pemafibrate Inhibits Stent Inflammation and Restenosis Assessed by Multimodality Molecular-Microstructural Imaging. J Am Heart Assoc. 2021;10(20):e020834doi: 10.1161/JAHA.121.020834.
Iwata, H., Osborn, E. A., Ughi, G. J., Murakami, K., Goettsch, C., Hutcheson, J. D., Mauskapf, A., Mattson, P. C., Libby, P., Singh, S. A., Matamalas, J., Aikawa, E., Tearney, G. J., Aikawa, M., & Jaffer, F. A. (2021). Highly Selective PPARα (Peroxisome Proliferator-Activated Receptor α) Agonist Pemafibrate Inhibits Stent Inflammation and Restenosis Assessed by Multimodality Molecular-Microstructural Imaging. Journal of the American Heart Association, 10(20), e020834. https://doi.org/10.1161/JAHA.121.020834
Iwata, Hiroshi, et al. "Highly Selective PPARα (Peroxisome Proliferator-Activated Receptor α) Agonist Pemafibrate Inhibits Stent Inflammation and Restenosis Assessed by Multimodality Molecular-Microstructural Imaging." Journal of the American Heart Association vol. 10,20 (2021): e020834. doi: https://doi.org/10.1161/JAHA.121.020834
Iwata H, Osborn EA, Ughi GJ, Murakami K, Goettsch C, Hutcheson JD, Mauskapf A, Mattson PC, Libby P, Singh SA, Matamalas J, Aikawa E, Tearney GJ, Aikawa M, Jaffer FA. Highly Selective PPARα (Peroxisome Proliferator-Activated Receptor α) Agonist Pemafibrate Inhibits Stent Inflammation and Restenosis Assessed by Multimodality Molecular-Microstructural Imaging. J Am Heart Assoc. 2021 Oct 19;10(20):e020834. doi: 10.1161/JAHA.121.020834. Epub 2021 Oct 11. PMID: 34632804.
Copy Download .nbib Format: NLM
Share it on

J Am Heart Assoc. 2021 Oct 19;10(20):e020834. doi: 10.1161/JAHA.121.020834. Epub 2021 Oct 11.

Highly Selective PPARα (Peroxisome Proliferator-Activated Receptor α) Agonist Pemafibrate Inhibits Stent Inflammation and Restenosis Assessed by Multimodality Molecular-Microstructural Imaging.

Journal of the American Heart Association

Hiroshi Iwata, Eric A Osborn, Giovanni J Ughi, Kentaro Murakami, Claudia Goettsch, Joshua D Hutcheson, Adam Mauskapf, Peter C Mattson, Peter Libby, Sasha A Singh, Joan Matamalas, Elena Aikawa, Guillermo J Tearney, Masanori Aikawa, Farouc A Jaffer

Affiliations

  1. Center for Interdisciplinary Cardiovascular Sciences Cardiovascular Division Brigham and Women's Hospital Harvard Medical School Boston MA.
  2. Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.
  3. Cardiovascular Research CenterCardiology DivisionMassachusetts General HospitalHarvard Medical School Boston MA.
  4. Cardiology Division Beth Israel Deaconess Medical CenterHarvard Medical School Boston MA.
  5. Wellman Center for Photomedicine Massachusetts General HospitalHarvard Medical School Boston MA.
  6. Center for Excellence in Vascular Biology Cardiovascular Division Brigham and Women's Hospital Harvard Medical School Boston MA.
  7. Department of Human Pathology I.M. Sechenov First Moscow State Medical University of the Ministry of Health Moscow Russian Federation.
  8. Department of Pathology Massachusetts General HospitalHarvard Medical School Boston MA.
  9. Channing Division of Network Medicine Brigham and Women's HospitalHarvard Medical School Boston MA.

PMID: 34632804 DOI: 10.1161/JAHA.121.020834

Abstract

BACKGROUND New pharmacological approaches are needed to prevent stent restenosis. This study tested the hypothesis that pemafibrate, a novel clinical selective PPARα (peroxisome proliferator-activated receptor α) agonist, suppresses coronary stent-induced arterial inflammation and neointimal hyperplasia. METHODS AND RESULTS Yorkshire pigs randomly received either oral pemafibrate (30 mg/day; n=6) or control vehicle (n=7) for 7 days, followed by coronary arterial implantation of 3.5 × 12 mm bare metal stents (2-4 per animal; 44 stents total). On day 7, intracoronary molecular-structural near-infrared fluorescence and optical coherence tomography imaging was performed to assess the arterial inflammatory response, demonstrating that pemafibrate reduced stent-induced inflammatory protease activity (near-infrared fluorescence target-to-background ratio: pemafibrate, median [25th-75th percentile]: 2.8 [2.5-3.3] versus control, 4.1 [3.3-4.3],

Keywords: SPPARMα (selective peroxisome proliferator‐activated receptor alpha modulator alpha); coronary artery disease; inflammation; molecular imaging; optical coherence tomography; pemafibrate; restenosis

Publication Types

Grant support